Skip to content
AnalystLens

AbbVie Inc. 8-K Report, Financial Results (Feb 4, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 4, 2026
Period End
February 4, 2026
Security
ABBV
In the record · 2016–202610-K1110-Q328-K163

ABBV filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 163 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’16Nov ’16
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Feb ’25Feb ’25

01—Abstract

Summary

Summary of the 8-K filed February 4, 2026. Cited figures are marked; the original filing is the authoritative source.

AbbVie reported fourth-quarter and full-year 2025 results on February 4, 2026, showing continued strong top-line growth driven by its immunology and neuroscience franchises, though GAAP earnings were pressured by acquired IPR&D and milestone charges.

Full-year net revenues rose 8.6% on a reported basis to $61.16 billiona, with Skyrizi ($17.56B), Rinvoq ($8.30B) and Humira ($4.54B) leading immunology revenue of $30.41B, up 14.0%. Neuroscience grew 19.6% to $10.77B, while oncology was nearly flat (+1.5%) and aesthetics declined 6.1%. Fourth-quarter revenue reached $16.62B, up 10.0%, with Skyrizi and Rinvoq growing more than 29%, offset by a 25.9% decline in Humira and a 20.8% decline in Imbruvica.

Profitability was mixed. Full-year GAAP diluted EPS fell 1.3% to $2.36b, and adjusted diluted EPS fell 1.2% to $10.00. Both figures absorbed an unfavorable $2.76 per share impact from roughly $5.0 billion of acquired IPR&D and milestones expense, which is a recurring feature of AbbVie's business development strategy and makes year-over-year comparisons noisy.

Fourth-quarter GAAP EPS was $1.02c versus a GAAP loss in the prior-year period, which had included a large impairment, and adjusted EPS was $2.71 versus $2.16 a year earlier. Management guided 2026 adjusted diluted EPS to $14.37 to $14.57, excluding any future acquired IPR&D and milestone charges.

Beyond the financials, the filing highlights a voluntary three-year agreement with the Trump administration covering Medicaid pricing, direct-to-patient offerings, tariff exemption, and a $100 billiond U.S. R&D and capital investment commitment over the next decade. The company also disclosed regulatory submissions for Rinvoq in vitiligo and Aquipta in acute migraine in Europe, an FDA approval for Epkinly in follicular lymphoma, a mixed topline result for Epkinly in DLBCL (PFS improved but overall survival did not reach statistical significance), a licensing deal for RemeGen's PD-1/VEGF bispecific RC148, and the acquisition of a device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services.

02—Key points

Key Highlights

  1. Full-year 2025 net revenues of $61.16B, up 8.6% reported (8.5% operational), a record despite the second full year after the U.S. Humira loss of exclusivity.
  2. Immunology revenues of $30.41B (+14.0%) led by Skyrizi at $17.56B (+49.9%) and Rinvoq at $8.30B (+39.1%); Humira fell to $4.54B (-49.5%).
  3. Neuroscience grew 19.6% to $10.77B, with Botox Therapeutic at $3.77B, Vraylar at $3.62B, and Ubrelvy plus Qulipta combined at $2.31B.
  4. Full-year GAAP EPS of $2.36 (-1.3%) and adjusted EPS of $10.00 (-1.2%) were reduced by $2.76 per share from $5.0B of acquired IPR&D and milestone expense.
  5. Fourth-quarter adjusted EPS of $2.71 rose from $2.16, and Q4 revenue of $16.62B grew 10.0%, with Skyrizi (+32.5%) and Rinvoq (+29.5%) driving growth.
  6. 2026 adjusted diluted EPS guidance of $14.37 to $14.57 excludes any future acquired IPR&D and milestone charges.
  7. Policy and pipeline developments include a three-year U.S. government agreement with Medicaid pricing terms, tariff exemption, and a $100B U.S. investment pledge, along with EU/FDA filings for Rinvoq in vitiligo and an FDA approval for Epkinly in follicular lymphoma.

03—Questions

Frequently Asked Questions

  1. How did AbbVie perform financially in 2025?

    AbbVie posted record full-year net revenues of $61.16 billion, up 8.6% on a reported basis. Adjusted diluted EPS was $10.00, down 1.2%, and GAAP diluted EPS was $2.36, down 1.3%. Both EPS figures were reduced by $2.76 per share from acquired IPR&D and milestone expenses.

  2. What is driving growth, and what is the drag?

    Immunology (Skyrizi and Rinvoq) and neuroscience (Vraylar, Botox Therapeutic, Ubrelvy and Qulipta) are the main growth engines. Humira's steep decline, which fell 49.5% for the year, along with weakness in aesthetics (-6.1%) and oncology (Imbruvica down 14.3%), partially offset that growth.

  3. What is the 2026 outlook?

    AbbVie guided 2026 adjusted diluted EPS to a range of $14.37 to $14.57. The guidance excludes any acquired IPR&D and milestone charges that may be incurred during 2026, since management says these cannot be reliably forecast, so reported results could fall below the guided range if large deals close.

  4. Why are GAAP and adjusted EPS so different, and does this matter for investors?

    The gap comes mainly from non-cash intangible asset amortization (about $3.50 per share in 2025) and fair-value changes in contingent consideration ($3.56 per share). Investors should watch the adjusted figures for underlying trends, while recognizing that recurring acquired IPR&D charges are a real cost of AbbVie's business development model.

  5. What regulatory and policy events could affect the outlook?

    The three-year agreement with the Trump administration provides tariff exemption and future pricing protection in exchange for Medicaid price concessions and a $100 billion U.S. R&D and capital commitment. Pending regulatory submissions include Rinvoq for vitiligo, and the Epkinly DLBCL data (no statistically significant overall survival benefit) will require further discussions with regulators.

04—Continue

← View all 8-K filings